Cabozantinib Malate (CAS 1140909-48-3)

Application and positioning

Cabozantinib malate is a multi-kinase inhibitor of MET, VEGFR2, AXL and RET, supplied as the malate salt. It is used in oral tablets and capsules for advanced renal cell carcinoma, hepatocellular carcinoma and medullary thyroid cancer. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Dacomitinib (CAS 1110813-31-4)
• Galunisertib (CAS 700874-72-2)
• Ibrutinib (CAS 936563-96-1)
• Larotrectinib Sulfate (CAS 1223405-08-0)
• 4-[(6,7-Dimethoxyquinolin-4-yl)oxy]aniline (CAS 190728-25-7)
• 4-Chloro-6,7-dimethoxyquinoline (CAS 35654-56-9)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.